Results from a phase 2 trial found a drug-vaccine combination developed by Merck and Moderna cut the risk of recurrence or death in patients with severe melanomas by 49%.
Read the full post on Becker's Hospital Review - Healthcare News
Vaccine therapy from Merck, Moderna may cut risk of skin cancer recurrence in half
